# Vyripharm Testimony before the Food and Drug Administration

Jerry Bryant, President & Managing Member, Vyripharm Biopharmaceuticals



#### **Need for Uniform Federal Standards**







The wild west of California's cannabis delivery

#### **University of Baltimore Law Review**

Issues to Watch, Online Articles, and Series

Prophesizing Pot: LAX Marijuana Policy Highlights the Need for Uniformity

### **Need for Uniform Federal Standards**

- **Uniformity and normalization** FDA regulation can allow for flexible implementation, but resolve the patchwork of standards across the country.
- **Differentiation** Allows regulators, sellers, and consumers to properly distinguish recreational and medical products.

**Vyripharm's approach:** We have developed a method of analyzing the *quality* and *quantity* of components in cannabis products that can precisely measure compliance with product standards.




## Information and Standards Should Be Universally Accessible

- Accessibility any FDA scheme should provide regulatory guidelines and background information in a universally accessible and comprehensive manner.
- This is essential to ensure the entire supply chain has the best information and does its best to serve consumers.

**Vyripharm's Approach:** We have developed an interface and database that allows users to compare detailed reports on cannabis strains and products. It includes extensive information down to the strain, source, genotype, and phenotype of a particular plant.



### **Treat Medicine As Medicine**



## **Need for Clear Product Labeling**

- Clarity any regulatory scheme should also include clear guidelines for product labeling.
- This will allow consumers to differentiate products and enable better tracking to test product effectiveness.

**Vyripharm's approach:** We've created a method of labeling cannabis products that clearly displays key components and component levels.

